11 January 2019 - - US-based Endologix, Inc. (NASDAQ: ELGX), a developer of treatments for aortic disorders, TODAY has appointed John D. Zehren as the company's chief commercial officer, the company said.

Zehren brings to Endologix more than twenty years of commercial, sales and marketing, and business development experience in the medical device industry.

Most recently, he served as vice president of sales, Americas at Medtronic Neurovascular and was a senior member of the company's Neurovascular Management Board.

While at Medtronic, he developed and implemented a strategic commercial plan to double revenue in five years.

Prior to that, he spent five years as vice president of Sales at Covidien and ev3. Earlier in his distinguished career, Zehren spent over a decade at Edwards Lifesciences, the last four years of which were in the role of vice president of Sales and Marketing.

Zehren earned his Bachelor of Arts in Biology from College of St. Thomas in Minnesota.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms.